AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Cellbxhealth PLC
Video analysis: ANPCF
All videosNo video analysis for this stock yet. Request one from our team.
News: ANPCF
CelLBxHealth's blood test spots hard-to-detect cells from brain tumours
An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company. Glioblastoma rarely spreads beyond the brain, which had made blood-based detection of the disease an unlikely prospect.
CelLBxHealth study detects drug targets on cancer cells rivals would miss
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company, said an independent study had shown its Parsortix system can detect the biological targets used by a fast-growing class of cancer drugs on tumour cells captured from patients' blood. The peer-reviewed research, published in The Journal of Liquid Biopsy, was carried out by researchers at Trinity College Dublin and St James's Hospital, Dublin.
CelLBxHealth moves from cutting to converting
The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is done.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.
CelLBxHealth reaffirms revenue guidance
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief executive. The figure would represent a 50% increase on 2025.
Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset centred on cost reduction and a shift towards partner-led commercialisation of its Parsortix platform.
CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 million, underpinned by a commercial pipeline that has expanded 22% over the last quarter. The AIM-listed company has emerged from a year-long restructuring sharper and leaner, having cut its cost base substantially during 2025 and recruited new leadership to drive a partnership-focused strategy centred on pharmaceutical and diagnostic companies rather than research income.
